Sumatriptan and other drugs used in migraine treatment.
C
C
Green
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D000075202:Contraindications; D003533:Cyproheptadine / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008784:Methysergide / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D018170:Sumatriptan; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000929:Antidepressive Agents, Tricyclic; D002121:Calcium Channel Blockers; D007211:Indoles; D008996:Monoamine Oxidase Inhibitors; D013449:Sulfonamides; D014662:Vasoconstrictor Agents; D003533:Cyproheptadine; D018170:Sumatriptan; D003000:Clonidine; D008784:Methysergide